InvestSMART

Nova Eye Medical Limited (ASX:EYE)

ALERT: Price-sensitive ASX Announcement for EYE
Current share price for EYE : $0.130 -0.013 (-8.77%)+
Announcement
Release
26 Aug 2026 5:04PM
Price at Release
$0.143
Full Release
download
Summary
Nova Eye Medical Limited reported a 26% increase in full-year sales to A$34.9 million for the financial year ending 30 June 2026. The company achieved a positive EBITDA of A$0.2 million in the second half of the year but had a full-year EBITDA loss of A$2.0 million, an improvement of A$3.5 million from the previous year. Nova Eye Medical reaffirmed its FY27 guidance, expecting sales between US$26 million and US$31 million, excluding China, and aims for positive EBITDA. The company has sufficient liquidity to support its growth targets, with a focus on the USA market where its iTrack™ technology is used in approximately 3% to 5% of glaucoma surgeries. Nova Eye Medical is committed to advancing ophthalmic treatment technologies globally.
Key Points
  • Full-year sales of A$34.9 million, up 26%.
  • Positive EBITDA of A$0.2 million in H2 FY26.
  • Full-year EBITDA loss of A$2.0 million, improved by A$3.5 million.
  • FY27 guidance: Sales between US$26 million and US$31 million, excluding China.
  • Sufficient liquidity with A$3.75 million in cash and debt facilities.
  • Scope for growth in USA market with iTrack™ technology.
  • Focus on advanced ophthalmic treatments globally.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.